Peter Alexandersen

7.8k citations

83 papers · 5.4k indexed · 1 hit paper · h-index 40

Orthopedics and Sports Medicine top 0.2%
- Bone health and osteoporosis research 32
Endocrinology, Diabetes and Metabolism top 0.5%
- Menopause: Health Impacts and Treatments 15
Oncology top 2%
- Bone health and treatments 19
Rheumatology top 1%
- Osteoarthritis Treatment and Mechanisms 17
- Rheumatoid Arthritis Research and Therapies 7
Nephrology top 2%
Genetics
- Estrogen and related hormone effects 21
Molecular Biology
- Bone Metabolism and Diseases 17
Pharmacology
- Inflammatory mediators and NSAID effects 7

Co-authors: Claus Christiansen Yu Z. Bagger László B. Tankó I. Byrjalsen Jens Haarbo Dennis B. Henriksen Gerong Qin M.A. Karsdal
Cited by: Orthopedics and Sports Medicine Endocrinology, Diabetes and Metabolism Oncology
Journals: Bone (13 papers)Osteoarthritis and Cartilage (9 papers)Climacteric (6 papers)
Partner nations: Denmark United States United Kingdom

In The Last Decade

Peter Alexandersen

80 papers receiving 5.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Peter Alexandersen

Since Specialization

Citations

This map shows the geographic impact of Peter Alexandersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Alexandersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Alexandersen more than expected).

Fields of papers citing papers by Peter Alexandersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Alexandersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Alexandersen. The network helps show where Peter Alexandersen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Alexandersen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Alexandersen Line = papers co-authored together Peter Alexandersen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial Osteoarthritis and Cartilage ·Asger Reinstrup Bihlet,Yves Henrotin,Chi-Tang Hung,Peter Alexandersen,Olivier Godeaux,K. Swart,François Rieger,Carole Nicco	2025	0
2	A phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in patients with symptomatic knee osteoarthritis Osteoarthritis and Cartilage ·Asger Reinstrup Bihlet,Xinjian Huang,Johannes Buchwälder,K. Swart,Nina Capone Singleton,J.R. Andersen,Bhintra Thakur,Jesus JA Jauregui,Alan Brett,Peter Alexandersen	2024	5
3	The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial Osteoarthritis and Cartilage ·Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,Alan Reynolds,政司大下,Peter Alexandersen,K. Swart,Robert J. Moots,Philip G. Conaghan	2024	7
4	POS1361 THE INFLUENCE OF BASELINE DEMOGRAPHICS ON VARIABILITY OF OA PAIN ASSESSED BY WOMAC PAIN CHANGE FROM BASELINE IN INTERVENTIONAL TRIALS Annals of the Rheumatic Diseases ·Asger Reinstrup Bihlet,Peter Alexandersen,J.R. Andersen,Ж. Ф. Гангхоффер,M.A. Karsdal,Aurora Vadillo	2023	0
5	Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD Alzheimer s Research & Therapy ·Everard G.B. Vijverberg,Kaize Yu,Asger Reinstrup Bihlet,Kim Henriksen,Frank Weber,Katharina Fuchs,John Harrison,Kerstin Kühn‐Wache,Peter Alexandersen,Niels D. Prins,Philip Scheltens	2021	27
6	Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis Journal of the American Academy of Dermatology ·Kenneth G. Saag,T. J. de Villiers,Peter Alexandersen,Heidi Jacobe,Carrie Kovarik,Victoria P. Werth,Albert Leung,Merel Godelieve Voth,Shubha Baravani,Deborah M. Gurner	2020	2
7	MRI analysis from two phase 3 randomized clinical trials; treatment of symptomatic knee osteoarthritis with oral salmon calcitonin Osteoarthritis and Cartilage ·M.A. Karsdal,Erik B. Dam,I. Byrjalsen,Asger Reinstrup Bihlet,J.R. Andersen,B.J. Riis,Peter Alexandersen,Anne‐Christine Bay‐Jensen,A. Ibranyi-Kiss	2015	1
8	Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials Osteoarthritis and Cartilage ·M.A. Karsdal,I. Byrjalsen,Peter Alexandersen,Asger Reinstrup Bihlet,J.R. Andersen,B.J. Riis,Anne‐Christine Bay‐Jensen,Claus Christiansen	2015	101
9	Association between joint space width, Kellgren-Lawrence score, pain and progression in osteoarthritis subjects from two phase III studies – a clinical study reference database Osteoarthritis and Cartilage ·Peter Alexandersen,I. Byrjalsen,Anne‐Christine Bay‐Jensen,Johansson Christine,J.R. Andersen,B.J. Riis,A. Ibranyi-Kiss,M.A. Karsdal	2014	0
10	Breast density changes associated with postmenopausal hormone therapy Menopause The Journal of The North American Menopause Society ·Mads Nielsen,Paola C. Pettersen,Peter Alexandersen,Gopal Karemore,Ros Anita Kartini Mohamed,Marco Loog,C. Christiansen	2010	6
11	Effect of microdose transdermal 17β-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women Menopause The Journal of The North American Menopause Society ·Matthias Schaefers,二郎魚住,Peter Alexandersen,Claus Christiansen	2009	11
12	New sequence variants associated with bone mineral density Nature Genetics ·Unnur Styrkársdóttir,Bjarni V. Halldórsson,Sólveig Grétarsdóttir,Daníel F. Guðbjartsson,G. Bragi Walters,Þorvaldur Ingvarsson,Þorbjörg Jónsdóttir,Jona Saemundsdottir,Steinunn Snorradóttir,Tuan V. Nguyen,Peter Alexandersen,Jeffrey R. Gulcher,John A. Eisman,Kaan Alpaslan Yamanoğlu,Gunnar Sigurðsson,Augustine Kong,Unnur Thorsteinsdottir,Kāri Stefánsson	2008	255
13	The influence of smoking on uterine bleeding during continuous and interrupted oral hormone therapy Climacteric ·N. H. Bjarnason,Henrik L. Jørgensen,I. Byrjalsen,Peter Alexandersen,Claus Christiansen	2007	3
14	The long-term impact of 2 – 3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women Climacteric ·Peter Alexandersen,László B. Tankó,Yu Z. Bagger,Gerong Qin,Claus Christiansen	2006	34
15	The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study Osteoporosis International ·Yu Z. Bagger,László B. Tankó,Peter Alexandersen,Henrik B. Hansen,Gerong Qin,Claus Christiansen	2005	63
16	Strontium treatment has a pronounced Effect on cartilage degradation in postmenopausal women Open Repository and Bibliography (University of Liège) ·Peter Alexandersen,László B. Tankó,Yu Z. Bagger,Henrik B. Hansen,Jean‐Yves Reginster	2004	1
17	Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study Bone ·Yu Z. Bagger,László B. Tankó,Peter Alexandersen,Henrik B. Hansen,修也野村,Pernille Ravn,Per Qvist,John А. Kanis,Claus Christiansen	2004	140
18	Raloxifene and estrogen reduces progression of advanced atherosclerosis — a study in ovariectomized, cholesterol-fed rabbits Atherosclerosis ·Nina Hannover Bjarnason,Jens Haarbo,I. Byrjalsen,Peter Alexandersen,Raymond F. Kauffman,Claus Christiansen	2001	28
19	Ipriflavone and Osteoporosis—Reply JAMA ·Peter Alexandersen,Bente Juel Riis	2001	1
20	Ipriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women Open Repository and Bibliography (University of Liège) ·Peter Alexandersen,Anne Toussaint,Jean‐Yves Reginster,C. Christiansen,(unknown),C. Gennari,C. Roux,J. Fechtenbaum	2000	1

About Peter Alexandersen

Peter Alexandersen is a scholar working on Orthopedics and Sports Medicine, Endocrinology, Diabetes and Metabolism, Rheumatology, Oncology and Genetics, having authored 83 papers that have together received 5.4k indexed citations. Recurring topics across this work include Bone health and osteoporosis research (32 papers), Estrogen and related hormone effects (21 papers), Bone health and treatments (19 papers), Osteoarthritis Treatment and Mechanisms (17 papers), Bone Metabolism and Diseases (17 papers), Menopause: Health Impacts and Treatments (15 papers), Inflammatory mediators and NSAID effects (7 papers) and Rheumatoid Arthritis Research and Therapies (7 papers). The work is most often cited by research in Orthopedics and Sports Medicine (2.1k citations), Endocrinology, Diabetes and Metabolism (1.5k citations), Oncology (1.5k citations), Rheumatology (716 citations) and Nephrology (243 citations). Peter Alexandersen has collaborated with scholars based in Denmark, United States and United Kingdom. Frequent co-authors include Claus Christiansen, Yu Z. Bagger, László B. Tankó, I. Byrjalsen, Jens Haarbo, Dennis B. Henriksen, Gerong Qin, M.A. Karsdal, Per Qvist and Philip J. Larsen. Their work appears in journals such as Bone, Osteoarthritis and Cartilage, Climacteric, Menopause The Journal of The North American Menopause Society and Osteoporosis International.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact